Nevro (NVRO) Tops Q4 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 4:05 PM ESTREDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.
Recent Highlights
Fourth Quarter 2020 Worldwide Revenue of $109.7 Million; Decrease of 4% Compared to Prior Year Fourth Quarter 2020 Net Loss from Operations of $0.9 Million; Fourth Quarter 2020 Non-GAAP Adjusted EBITDA of $15.7 Million Company Provides Full-Year 2021 Revenue Guidance of $430 Million to $450 Million Company... More